Cargando…

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients

Invasive fungal diseases (IFDs) are one of the leading causes of death in lung transplant recipients. This study aimed to compare the antifungal prophylactic effectiveness, intrapulmonary and plasma levels of voriconazole with posaconazole in lung transplant recipients. This retrospective cohort stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Chunrong, Lian, Qiaoyan, Chen, Ao, Zhao, Boxin, Zhou, Shouning, Cai, Yuhang, Xie, Hui, Wei, Li, Li, Shiyue, He, Jianxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437723/ https://www.ncbi.nlm.nih.gov/pubmed/36036471 http://dx.doi.org/10.1093/mmy/myac041

Ejemplares similares

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Efficacy of different durations of antifungal prophylaxis with nebulized amphotericin B after lung transplantation: a retrospective cohort study
por: Ju, Chunrong, et al.
Publicado: (2023)

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
por: Yi, Whitley M., et al.
Publicado: (2017)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2023)

Epidemiology and Prognosis of Invasive Fungal Disease in Chinese Lung Transplant Recipients
por: Ju, Chunrong, et al.
Publicado: (2021)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

The Effect of Posaconazole, Itraconazole and Voriconazole in the Culture Medium on Aspergillus fumigatus Triazole Resistance
por: Mroczyńska, Martyna, et al.
Publicado: (2020)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis
por: Martínez-Casanova, Javier, et al.
Publicado: (2018)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis
por: Maertens, Johan A., et al.
Publicado: (2023)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients
por: Zhao, Yi‐Chang, et al.
Publicado: (2020)

Intrapulmonary concentration of enrofloxacin in healthy calves
por: OTOMARU, Konosuke, et al.
Publicado: (2015)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study
por: Ju, Chunrong, et al.
Publicado: (2022)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia
por: Gheith, Soukeina, et al.
Publicado: (2014)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
por: Märtson, Anne‐Grete, et al.
Publicado: (2019)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole
por: Szekalska, Marta, et al.
Publicado: (2019)

Synthesis of Isomeric and Potent Impurities of the Triazole-Based Antifungal Drug Voriconazole
por: Sundaram, Dhanraj T. S. S., et al.
Publicado: (2015)

Antifungal management in ICU: careful follow-up of voriconazole prescription needed!
por: Reizine, Florian, et al.
Publicado: (2023)

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model
por: Dvořáčková, Eliška, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d9t9nash050592mauev5i21lnu